Last reviewed · How we verify
ropivacaïne 0,5 %
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.
At a glance
| Generic name | ropivacaïne 0,5 % |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers, thereby stabilizing the neuronal membrane and preventing depolarization. This action blocks conduction of sensory and motor nerve impulses in a dose-dependent manner. It is an amide-type local anesthetic with a long duration of action and relatively low systemic toxicity compared to some alternatives.
Approved indications
- Local and regional anesthesia for surgical procedures
- Peripheral nerve blocks
- Epidural anesthesia
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Headache
- Systemic toxicity (CNS and cardiac effects at high doses)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropivacaïne 0,5 % CI brief — competitive landscape report
- ropivacaïne 0,5 % updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI